BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23992401)

  • 21. Novel therapeutic approach for cancer using four cardiovascular hormones.
    Vesely DL; Clark LC; Garces AH; McAfee QW; Soto J; Gower WR
    Eur J Clin Invest; 2004 Oct; 34(10):674-82. PubMed ID: 15473892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of human squamous lung cancer cells.
    Vesely BA; Fitz SR; Gower WR; Vesely DL
    Cancer Lett; 2006 Feb; 233(2):226-31. PubMed ID: 15893414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells.
    Vesely BA; Alli AA; Song SJ; Gower WR; Sanchez-Ramos J; Vesely DL
    Eur J Clin Invest; 2005 Nov; 35(11):700-10. PubMed ID: 16269020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urodilatin and four cardiac hormones decrease human renal carcinoma cell numbers.
    Vesely BA; Eichelbaum EJ; Alli AA; Sun Y; Gower WR; Vesely DL
    Eur J Clin Invest; 2006 Nov; 36(11):810-9. PubMed ID: 17032349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Skelton WP; Lenz A; Wang H; Vesely DL
    Anticancer Res; 2009 Apr; 29(4):971-5. PubMed ID: 19414334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vessel dilator and kaliuretic peptide inhibit ERK 1/2 activation in human prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2006; 26(5A):3217-22. PubMed ID: 17094432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiac hormones are potent inhibitors of secreted frizzled-related protein-3 in human cancer cells.
    Skelton WP; Skelton M; Vesely DL
    Exp Ther Med; 2013 Feb; 5(2):475-478. PubMed ID: 23408665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four cardiac hormones cause death of human cancer cells but not of healthy cells.
    Skelton WP; Pi GE; Vesely DL
    Anticancer Res; 2011 Feb; 31(2):395-402. PubMed ID: 21378317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations.
    Vesely DL; San Miguel GI; Hassan I; Schocken DD
    Horm Metab Res; 2002 May; 34(5):245-9. PubMed ID: 12063637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Stimulation of C-fos and jun B proto-oncogenes: potential role of TRH effects in clone cell line with prolactin (GH3B6)].
    Passegué E; Laverrière JN; Boulla G; Gourdji D
    C R Seances Soc Biol Fil; 1995; 189(1):97-110. PubMed ID: 7648371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four cardiac hormones eliminate 4-fold more human glioblastoma cells than the green mamba snake peptide.
    Vesely BA; Eichelbaum EJ; Alli AA; Sun Y; Gower WR; Vesely DL
    Cancer Lett; 2007 Aug; 254(1):94-101. PubMed ID: 17399891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice.
    Eichelbaum EJ; Sun Y; Alli AA; Gower WR; Vesely DL
    Eur J Clin Invest; 2008 Aug; 38(8):562-70. PubMed ID: 18717826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of albumin, total protein, and beta(2)-microglobulin in patients with congestive heart failure.
    Vesely DL; Perez-Lamboy GI; Schocken DD
    J Card Fail; 2001 Mar; 7(1):55-63. PubMed ID: 11264551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A peptide fragment of ependymin neurotrophic factor uses protein kinase C and the mitogen-activated protein kinase pathway to activate c-Jun N-terminal kinase and a functional AP-1 containing c-Jun and c-Fos proteins in mouse NB2a cells.
    Adams DS; Hasson B; Boyer-Boiteau A; El-Khishin A; Shashoua VE
    J Neurosci Res; 2003 May; 72(3):405-16. PubMed ID: 12692907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiac hormones for the treatment of cancer.
    Vesely DL
    Endocr Relat Cancer; 2013 Jun; 20(3):R113-25. PubMed ID: 23533248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of anisomycin on activation of early response genes c-fos, c-jun, Egr-1 in cells transformed by E1A and cHa-ras oncogenes].
    Kukushkin AN; Svetlikova SB; Pospelov VA
    Mol Biol (Mosk); 2005; 39(1):80-8. PubMed ID: 15773551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells.
    Vesely BA; Alli A; Song S; Sanchez-Ramos J; Fitz SR; Gower WR; Vesely DL
    Cardiology; 2006; 105(4):226-33. PubMed ID: 16534199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells.
    Sun Y; Eichelbaum EJ; Wang H; Vesely DL
    Anticancer Res; 2006; 26(6B):4143-8. PubMed ID: 17201125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK.
    Deng T; Karin M
    Nature; 1994 Sep; 371(6493):171-5. PubMed ID: 8072547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical detection of RAS, JUN, FOS, and p53 oncoprotein expression in human colorectal adenomas and carcinomas.
    Magrisso IJ; Richmond RE; Carter JH; Pross CB; Gilfillen RA; Carter HW
    Lab Invest; 1993 Dec; 69(6):674-81. PubMed ID: 8264230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.